Search

Your search keyword '"De Sèze, Jerome"' showing total 163 results
Start Over Author "De Sèze, Jerome"
163 results on '"De Sèze, Jerome"'

7. Diagnosis and classification of optic neuritis

Author

Petzold, Axel, Fraser, Clare L, Abegg, Mathias, Alroughani, Raed, Alshowaeir, Daniah, Alvarenga, Regina, Andris, Cécile, Asgari, Nasrin, Barnett, Yael, Battistella, Roberto, Behbehani, Raed, Berger, Thomas, Bikbov, Mukharram M, Biotti, Damien, Biousse, Valerie, Boschi, Antonella, Brazdil, Milan, Brezhnev, Andrei, Calabresi, Peter A, Cordonnier, Monique, Costello, Fiona, Cruz, Franz M, Cunha, Leonardo Provetti, Daoudi, Smail, Deschamps, Romain, de Seze, Jerome, Diem, Ricarda, Etemadifar, Masoud, Flores-Rivera, Jose, Fonseca, Pedro, Frederiksen, Jette, Frohman, Elliot, Frohman, Teresa, Tilikete, Caroline Froment, Fujihara, Kazuo, Gálvez, Alberto, Gouider, Riadh, Gracia, Fernando, Grigoriadis, Nikolaos, Guajardo, José M, Habek, Mario, Hawlina, Marko, Martínez-Lapiscina, Elena H, Hooker, Juzar, Hor, Jyh Yung, Howlett, William, Huang-Link, Yumin, Idrissova, Zhannat, Illes, Zsolt, Jancic, Jasna, Jindahra, Panitha, Karussis, Dimitrios, Kerty, Emilia, Kim, Ho Jin, Lagrèze, Wolf, Leocani, Letizia, Levin, Netta, Liskova, Petra, Liu, Yaou, Maiga, Youssoufa, Marignier, Romain, McGuigan, Chris, Meira, Dália, Merle, Harold, Monteiro, Mário L R, Moodley, Anand, Moura, Frederico, Muñoz, Silvia, Mustafa, Sharik, Nakashima, Ichiro, Noval, Susana, Oehninger, Carlos, Ogun, Olufunmilola, Omoti, Afekhide, Pandit, Lekha, Paul, Friedemann, Rebolleda, Gema, Reddel, Stephen, Rejdak, Konrad, Rejdak, Robert, Rodriguez-Morales, Alfonso J, Rougier, Marie-Bénédicte, Sa, Maria Jose, Sanchez-Dalmau, Bernardo, Saylor, Deanna, Shatriah, Ismail, Siva, Aksel, Stiebel-Kalish, Hadas, Szatmary, Gabriella, Ta, Linh, Tenembaum, Silvia, Tran, Huy, Trufanov, Yevgen, van Pesch, Vincent, Wang, An-Guor, Wattjes, Mike P, Willoughby, Ernest, Zakaria, Magd, Zvornicanin, Jasmin, Balcer, Laura, and Plant, Gordon T

Published
2022
Full Text
View/download PDF

9. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Author

van der Walt, Anneke, Dwyer, Christopher, Buzzard, Katherine, Spies, Judith, Parratt, John, van Pesch, Vincent, Willekens, Barbara, Perrotta, Gaetano, Bartholomé, Emmanuel, Grand'Maison, Francois, Jacques, Francois, Giacomini, Paul, Vosoughi, Reza, Girard, Jean-Marc, de Seze, Jerome, Lebrun Frenay, Christine, Ruet, Aurelie, Laplaud, David-Axel, Reifschneider, Gerd, Wagner, Bert, Rauer, Sebastian, Pul, Refik, Seipelt, Maria, Berthele, Achim, Klotz, Luisa, Kallmann, Boris-Alexander, Paul, Friedemann, Achiron, Anat, Lus, Giacomo, Centonze, Diego, Patti, Francesco, Grimaldi, Luigi, Hupperts, Raymond, Frequin, Stephan, Fermont, Jiske, Madueno, Sara Eichau, Alonso Torres, Ana Maria, Costa-Frossard França, Lucienne, Meca-Lallana, Jose Eustasio, Ruiz, Luis Brieva, Pearson, Owen, Rog, David, Evangelou, Nikolaos, Ismail, Azza, Lathi, Ellen, Fox, Edward, Leist, Thomas, Sloane, Jacob, Wu, Gregory, Khatri, Bhupendra, Steingo, Brian, Thrower, Ben, Gudesblatt, Mark, Calkwood, Jonathan, Bandari, Daniel, Scagnelli, John, Laganke, Christopher, Robertson, Derrick, Kipp, Lucas, Belkin, Martin, Cohan, Stanley, Goldstick, Lawrence, Courtney, Ardith, Vargas, Wendy, Sylvester, Andrew, Srinivasan, Jayshri, Kannan, Meena, Picone, Maryann, English, Jeffrey, Napoli, Salvatore, Balabanov, Roumen, Zaydan, Islam, Nicholas, Jacqueline, Kaplan, Jeffrey, Lublin, Fred, Riser, Emily, Miller, Tamara, Alvarez, Enrique, Wray, Sibyl, Gross, Jeffrey, Pawate, Siddharama, Hersh, Carrie, McCarthy, Lucas, Crayton, Heidi, Graves, Jennifer, Foley, John F, Defer, Gilles, Ryerson, Lana Zhovtis, Cohen, Jeffrey A, Arnold, Douglas L, Butzkueven, Helmut, Cutter, Gary, Giovannoni, Gavin, Killestein, Joep, Wiendl, Heinz, Smirnakis, Karen, Xiao, Shan, Kong, George, Kuhelj, Robert, and Campbell, Nolan

Published
2022
Full Text
View/download PDF

10. COVID-19 exposure in SARS-CoV-2-seropositive hospital staff members during the first pandemic wave at Strasbourg University Hospital, France

Author

Velay, Aurélie, Gallais, Floriane, Wendling, Marie-Josée, Bayer, Sophie, Reix, Nathalie, Schneider, Anne, Glady, Ludovic, Collongues, Nicolas, Lessinger, Jean-Marc, Hansmann, Yves, Kling-Pillitteri, Laurence, De Sèze, Jérome, Gonzalez, Maria, Schmidt-Mutter, Catherine, Meyer, Nicolas, and Fafi-Kremer, Samira

Published
2022
Full Text
View/download PDF

11. Myelin-oligodendrocyte glycoprotein antibody-associated disease

Author

Marignier, Romain, Hacohen, Yael, Cobo-Calvo, Alvaro, Pröbstel, Anne-Katrin, Aktas, Orhan, Alexopoulos, Harry, Amato, Maria-Pia, Asgari, Nasrin, Banwell, Brenda, Bennett, Jeffrey, Brilot, Fabienne, Capobianco, Marco, Chitnis, Tanuja, Ciccarelli, Olga, Deiva, Kumaran, De Sèze, Jérôme, Fujihara, Kazuo, Jacob, Anu, Kim, Ho Jin, Kleiter, Ingo, Lassmann, Hans, Leite, Maria-Isabel, Linington, Christopher, Meinl, Edgar, Palace, Jacqueline, Paul, Friedemann, Petzold, Axel, Pittock, Sean, Reindl, Markus, Sato, Douglas Kazutoshi, Selmaj, Krzysztof, Siva, Aksel, Stankoff, Bruno, Tintore, Mar, Traboulsee, Anthony, Waters, Patrick, Waubant, Emmanuelle, Weinshenker, Brian, Derfuss, Tobias, Vukusic, Sandra, and Hemmer, Bernhard

Published
2021
Full Text
View/download PDF

13. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Author

Plavina, Tatiana, Muralidharan, Kumar Kandadi, Kuesters, Geoffrey, Mikol, Daniel, Evans, Karleyton, Subramanyam, Meena, Nestorov, Ivan, Chen, Yi, Dong, Qunming, Ho, Pei-Ran, Amarante, Diogo, Adams, Alison, De Sèze, Jerome, Fox, Robert, Gold, Ralf, Jeffery, Douglas, Kappos, Ludwig, Montalban, Xavier, Weinstock-Guttman, Bianca, Hartung, Hans-Peter, and Cree, Bruce AC

Subjects
Multiple Sclerosis, Brain Disorders, Neurodegenerative, Clinical Research, Neurosciences, Clinical Trials and Supportive Activities, Inflammatory and immune system, Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunologic Factors, Integrin alpha4, Lymphocyte Count, Lymphocyte Subsets, Male, Middle Aged, Natalizumab, Retrospective Studies, Secondary Prevention, Treatment Outcome, Vascular Cell Adhesion Molecule-1, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo characterize the reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics in patients with multiple sclerosis (MS) following therapy interruption.MethodsPharmacokinetic/pharmacodynamic data were collected in the Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis (AFFIRM) (every 12 weeks for 116 weeks) and Randomized Treatment Interruption of Natalizumab (RESTORE) (every 4 weeks for 28 weeks) studies. Serum natalizumab and soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured using immunoassays. Lymphocyte subsets, α4-integrin expression/saturation, and vascular cell adhesion molecule-1 (VCAM-1) binding were assessed using flow cytometry.ResultsBlood lymphocyte counts (cells/L) in natalizumab-treated patients increased from 2.1 × 109 to 3.5 × 109. Starting 8 weeks post last natalizumab dose, lymphocyte counts became significantly lower in patients interrupting treatment than in those continuing treatment (3.1 × 109 vs 3.5 × 109; p = 0.031), plateauing at prenatalizumab levels from week 16 onward. All measured cell subpopulation, α4-integrin expression/saturation, and sVCAM changes demonstrated similar reversibility. Lymphocyte counts remained within the normal range. Ex vivo VCAM-1 binding to lymphocytes increased until ≈16 weeks after the last natalizumab dose, then plateaued, suggesting reversibility of immune cell functionality. The temporal appearance of gadolinium-enhancing lesions was consistent with pharmacodynamic marker reversal.ConclusionsNatalizumab's effects on peripheral immune cells and pharmacodynamic markers were reversible, with changes starting 8 weeks post last natalizumab dose; levels returned to those observed/expected in untreated patients ≈16 weeks post last dose. This reversibility differentiates natalizumab from MS treatments that require longer reconstitution times. Characterization of the time course of natalizumab's biological effects may help clinicians make treatment sequencing decisions.Classification of evidenceThis study provides Class III evidence that the pharmacodynamic markers of natalizumab are reversed ≈16 weeks after stopping natalizumab.

Published
2017

16. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

Author

Kaufman, Michael, Cree, Bruce AC, De Sèze, Jerome, Fox, Robert J, Gold, Ralf, Hartung, Hans-Peter, Jeffery, Douglas, Kappos, Ludwig, Montalbán, Xavier, Weinstock-Guttman, Bianca, Ticho, Barry, Duda, Petra, Pace, Amy, and Campagnolo, Denise

Subjects
Clinical Trials and Supportive Activities, Biomedical Imaging, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Female, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Radiography, Recurrence, Gadolinium-enhancing lesions, MRI, Multiple sclerosis, Treatment interruption, Clinical Sciences, Neurosciences, Neurology & Neurosurgery
Abstract

The objective of this study is to characterize the timing and extent of radiologic MS disease recurrence during the 24-week natalizumab treatment interruption period in RESTORE. RESTORE was a randomized, partially placebo-controlled exploratory study. Natalizumab-treated patients with no gadolinium-enhancing (Gd+) lesions at screening (n = 175) were randomized 1:1:2 to continue natalizumab (n = 45), switch to placebo (n = 42), or switch to other therapies (n = 88) for 24 weeks. MRI assessments were performed every 4 weeks. Predictors of increased numbers of Gd+ lesions during natalizumab treatment interruption were evaluated. The numbers of Gd+ lesions were compared with retrospectively collected pre-natalizumab MRI reports and data from placebo-treated patients from two historical randomized clinical trials. Gd+ lesions were detected in 0 % (0/45) of natalizumab patients, 61 % (25/41) of placebo patients, and 48 % (39/81) of other-therapies patients during the randomized treatment period. Gd+ lesions were detected starting at week 12; most were observed at week 16 or later. Thirteen percent (14/107) of patients had >5 Gd+ lesions on ≥1 (of 6) scans during the randomized treatment period versus 7 % (7/107) of patients pre-natalizumab (based on medical record of a single scan). Younger patients and those with more Gd+ lesions pre-natalizumab were more likely to have increased MRI activity. Distribution of total and persistent Gd+ lesions in RESTORE patients was similar to placebo-treated historical control patients. In most patients, recurring radiological disease activity during natalizumab interruption did not exceed pre-natalizumab levels or levels seen in historical control patients.

Published
2015

22. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Author

Amato, Maria Pia, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Becher, Burkhard, Bethoux, François, Brandt, Alexander, Brownlee, Wallace, Calabresi, Peter, Chatway, Jeremy, Chien, Claudia, Chitnis, Tanuja, Ciccarelli, Olga, Cohen, Jeffrey, Comi, Giancarlo, Correale, Jorge, De Sèze, Jerome, De Stefano, Nicola, Fazekas, Franz, Flanagan, Eoin, Freedman, Mark, Fujihara, Kazuo, Galetta, Steven, Goldman, Myla, Greenberg, Benjamin, Hartung, Hans-Peter, Hemmer, Bernhard, Henning, Anke, Izbudak, Izlem, Kappos, Ludwig, Lassmann, Hans, Laule, Cornelia, Levy, Michael, Lublin, Fred, Lucchinetti, Claudia, Lukas, Carsten, Marrie, Ruth Ann, Miller, Aaron, Miller, David, Montalban, Xavier, Mowry, Ellen, Ourselin, Sebastien, Paul, Friedemann, Pelletier, Daniel, Ranjeva, Jean-Philippe, Reich, Daniel, Reingold, Stephen, Rocca, Maria Assunta, Rovira, Alex, Schlaerger, Regina, Soelberg Sorensen, Per, Sormani, Maria, Stuve, Olaf, Thompson, Alan, Tintoré, Mar, Traboulsee, Anthony, Trapp, Bruce, Trojano, Maria, Uitdehaag, Bernard, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian, Wheeler-Kingshott, Claudia Gandini, Xu, Junqian, Cohen, Jeffrey A, Reingold, Stephen C, and Weinshenker, Brian G

Published
2019
Full Text
View/download PDF

24. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial

Author

Day, Timothy, Spies, Judith, Roberts, Leslie, Van Damme, Philip, Van den Bergh, Peter YK, Maertens de Noordhout, Alain, Dionne, Annie, Larue, Sandrine, Massie, Rami, Melanson, Michel, Camu, William, De Seze, Jérôme, Le Masson, Gwendal, Pouget, Jean, Schmidt, Jens, Kimiskidis, Vasilios K, Chapman, Joab, Drory, Vivian E, Fazio, Raffaella, Gallia, Francesca, Kusunoki, Susumu, Mori, Masahiro, Iijima, Masahiro, Okamoto, Tomoko, Baba, Masayuki, Faber, Catharina G, van Schaik, Ivo N, Fryze, Waldemar, Motta, Ewa, Selmaj, Krzysztof, Casasnovas, Carlos, Sola, Antonio Guerrero, Illa, Isabel, Holt, James, Miller, James AL, Lunn, Michael P, Brannagan, Thomas H, III, Brown, Martin, Kelemen, John, Iyadurai, Stanley, Rezania, Kourosh, Sharma, Khema R, Tandan, Rup, Gudesblatt, Mark, Lawson, Victoria, Amato, Anthony A, Hughes, Richard, Dalakas, Marinos C, Merkies, Ingemar, Latov, Norman, Léger, Jean-Marc, Nobile-Orazio, Eduardo, Sobue, Gen, Genge, Angela, Cornblath, David, Merschhemke, Martin, Ervin, Carolyn Marie, Agoropoulou, Catherine, and Hartung, Hans-Peter

Published
2018
Full Text
View/download PDF

28. The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers

Author

Brocard, Guillaume, Casey, Romain, Dufay, Nathalie, Marignier, Romain, Michel, Laure, Hisbergues, Michael, Ayrignac, Xavier, Lehmann, Sylvain, Thouvenot, Eric, Gallot, Geraldine, Collongues, Nicolas, Herpe, Yves-Edouard, Lebrun-Frenay, Christine, Cotton, François, De Sèze, Jérôme, Guillemin, Francis, Moreau, Thibault, Pelletier, Jean, Stankoff, Bruno, Vukusic, Sandra, Zephir, Hélène, and Laplaud, David

Published
2023
Full Text
View/download PDF

30. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus

Author

De Sèze, Jerome, primary, Suchet, Laurent, additional, Mekies, Claude, additional, Manchon, Eric, additional, Labauge, Pierre, additional, Guennoc, Anne-Marie, additional, Defer, Gilles, additional, Clavelou, Pierre, additional, Castelnovo, Giovanni, additional, Bourre, Bertrand, additional, Bensa-Koscher, Caroline, additional, Al Khedr, Abdullatif, additional, Le Mao, Julie, additional, Villemur, Lauriane, additional, Bouée, Stephane, additional, Luciani, Laura, additional, and Vermersch, Patrick, additional

Published
2022
Full Text
View/download PDF

31. Longitudinal Change Detection: Inference on the Diffusion Tensor Along White-Matter Pathways

Author

Grigis, Antoine, Noblet, Vincent, Blanc, Fréderic, Heitz, Fabrice, de Seze, Jérome, Armspach, Jean-Paul, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Sudan, Madhu, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Vardi, Moshe Y., Series editor, Weikum, Gerhard, Series editor, Fichtinger, Gabor, editor, Martel, Anne, editor, and Peters, Terry, editor

Published
2011
Full Text
View/download PDF

35. Treatment of neuromyelitis optica: Review and recommendations

Author

Kimbrough, Dorlan J., Fujihara, Kazuo, Jacob, Anu, Lana-Peixoto, Marco A., Isabel Leite, Maria, Levy, Michael, Marignier, Romain, Nakashima, Ichiro, Palace, Jacqueline, de Seze, Jérôme, Stuve, Olaf, Tenembaum, Silvia N., Traboulsee, Anthony, Waubant, Emmanuelle, Weinshenker, Brian G., and Wingerchuk, Dean M.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results